Analyst Reco. Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
8.33 ^USD	+6.52%		+4.91%	-15.52%

04-18	Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing	MT
04-16	Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing	04-18	MT
Needham Raises Price Target on Recursion Pharmaceuticals to $17 From $15, Maintains Buy Rating	02-28	MT
TD Cowen Starts Recursion Pharmaceuticals With Market Perform Rating	01-26	MT
JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating	11-13	MT
Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating	11-10	MT
KeyBanc Adjusts Price Target on Recursion Pharmaceuticals to $15 From $12, Maintains Overweight Rating	13/07/23	MT
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $35 From $33, Maintains Buy Rating	13/07/23	MT
Morgan Stanley Lifts Price Target on Recursion Pharmaceuticals to $11 From $8 Amid NVIDIA Partnership, Keeps Equalweight Rating	13/07/23	MT
Keybanc Adjusts Price Target on Recursion Pharmaceuticals to $12 From $20, Keeps Overweight Rating	09/05/23	MT
Needham Starts Recursion Pharmaceuticals at Buy With $17 Price Target	16/03/23	MT
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $33 From $42, Maintains Buy Rating	02/02/23	MT
SVB Securities Adjusts Price Target on Recursion Pharmaceuticals to $8 From $9, Maintains Market Perform Rating	23/01/23	MT
Berenberg Discover AI Seminar	28/11/22	FA
Berenberg Bank Adjusts Recursion Pharmaceuticals Price Target to $42 From $38, Maintains Buy Rating	16/11/22	MT
Goldman Sachs Adjusts Price Target on Recursion Pharmaceuticals to $9 From $8, Maintains Neutral Rating	09/11/22	MT
KeyBanc Starts Recursion Pharmaceuticals at Overweight With $20 Price Target	16/09/22	MT
Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum	18/08/22	PR
Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $8 From $7, Keeps Neutral Rating	11/08/22	MT
Berenberg Bank Adjusts Recursion Pharmaceuticals' Price Target to $38 From $36, Maintains Buy Rating	22/06/22	MT
Goldman Sachs Lowers Recursion Pharmaceuticals' Price Target to $7 From $9, Neutral Rating Kept	24/05/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Analyst Reco.

Filters